Physicians at the AHA conference are firing back at Nissen’s controversial Avandia meta-analysis:
The validity of Dr. Nissen’s findings was challenged by Silvio E. Inzucchi, M.D., clinical director of the Section of Endocrinology at Yale. “Any minor manipulations to this information can be done to show either how much harm rosiglitazone is doing, or how much good it has done,” Dr. Inzucchi claimed.He said that in the Nissen paper researchers “took results from small trials, calculated the odds and they came up with a 43% increase in myocardial infarction.”
